Ehsan Rahimy News Today

Ehsan Rahimy, MD, outlines strategies for managing cases of high-risk PDR and DME, exploring new therapies and synergistic combinations with anti-VEGF and steroids for longer-lasting responses.

Ehsan Rahimy, MD, discusses challenges in managing longstanding nAMD patients rotating through anti-VEGF treatments, highlighting the promise of newer therapies like aflibercept 8mg and faricimab.

An expert retina specialist discusses challenges faced by DME patients showing suboptimal response to standard anti-VEGF treatment, emphasizing the need to reduce injection burden while preventing vision loss.

Experts discuss the recent PULSAR and PHOTON studies with high dose aflibercept (8mg) and how they educate patients about this treatment approach.

Experts discuss insurer mandated step therapy and how to navigate treatment options for patients with diabetic macular edema (DME).

Experts discuss clinical trials on the efficacy of faricimab and how they utilize this therapy in their practice.

Patients taking glucagon-like peptide-1 agonists were more likely to progress from nonproliferative diabetic retinopathy to proliferative disease or diabetic macular edema than those who took sodium-glucose cotransporter-2 inhibitors.

Experts discuss the results of Protocol T study comparing anti-vascular endothelial growth factor (Anti-VEGF) agents for the treatment of diabetic macular edema (DME).

Experts discuss the recent DRCR Protocol AC study comparing aflibercept monotherapy vs bevacizumab first therapy for patients with diabetic macular edema (DME).

NEW YORK — A retrospective study of more than 36,000 patients showed that geographic atrophy causes substantial disease burden, according to a speaker here.